<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934. For the quarterly period ended June 30, 1997
or
[_] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934. For the transition period from _______ to ______.
COMMISSION FILE NUMBER: 0-22419
-------
CARDIMA, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 94-3177883
- --------------------------------- --------------------
(State or Other Jurisdiction (I.R.S. Employer
of Incorporation or Organization) Identification No.)
47266 BENICIA STREET, FREMONT, CA 94538-7330
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (510) 354-0300
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) had been subject to such filing
requirements for the past 90 days. Yes No X
------ ------
As of July 31, 1997, there were 8,098,904 shares of Registrant's Common Stock
outstanding.
1
<PAGE>
CARDIMA, INC.
INDEX
<TABLE>
<CAPTION>
Page #
------
<S> <C>
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Balance Sheets as of June 30, 1997 and December 31, 1996 3
Statements of Operations for the three months and six months
ended June 30, 1997 and 1996 4
Statements of Cash Flows for the six months ended June 30, 1997 and 1996 5
Notes to Financial Statements 6
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS 8
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 23
Item 2. Changes in Securities 23
Item 3. Defaults Upon Senior Securities 23
Item 4. Submission of Matters to a Vote of Security Holders 23
Item 5. Other Information 24
Item 6. Exhibits and Reports on Form 8-K 24
SIGNATURES 25
INDEX TO EXHIBITS 26
EXHIBIT 11.1 27
EXHIBIT 27.1 28
</TABLE>
2
<PAGE>
PART I. FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS
CARDIMA, INC.
BALANCE SHEETS
(In thousands except share amounts)
<TABLE>
<CAPTION>
(1)
June 30, Dec. 31,
ASSETS 1997 1996
-------- --------
<S> <C> <C>
Current Assets: (unaudited)
Cash and cash equivalents $ 20,479 $ 907
Short-term investments 0 0
Accounts receivable, net of allowances for doubtful accounts
of $85 at June 30, 1997 and $30 at Dec. 31, 1996 161 68
Inventories 586 377
Other current assets 299 229
-------- --------
Total current assets 21,525 1,581
Property and equipment, net 2,187 1,400
Restricted cash 255 275
Other assets 223 708
-------- --------
Total assets $ 24,190 $ 3,964
======== ========
Liabilities and stockholders' equity (net capital deficiency)
Current liabilities:
Accounts payable $ 630 $ 1,113
Accrued compensation 573 513
Other current liabilities 94 94
Notes payable 8 1,682
Capital lease obligation - current portion 436 329
-------- --------
Total current liabilities 1,741 3,731
Deferred rent 114 139
Capital lease obligation - noncurrent portion 741 722
Commitments
Redeemable convertible preferred stock at amount paid in:
Series D redeemable convertible, 1,919,052 at December 31, 1996; none
at June 30, 1997 - 9,740
Stockholders' equity (net capital deficiency):
Preferred stock, $.001 par value; 5,000,000 shares authorized
Series A convertible, 428,567 shares issued and outstanding as of December 31, 1996;
none at June 30, 1997; at amount paid in - 2,949
Series B convertible, 333,333 shares issued and outstanding as of December 31, 1996;
none at June 30, 1997; at amount paid in - -
Series C convertible, 458,245 shares issued and outstanding as of December 31, 1996;
none at June 30, 1997; at amount paid in - 4,764
Common stock, $.001 par value; 25,000,000 shares authorized, 8,096,323 shares
issued and outstanding at June 30, 1997, 74,999 at December 31, 1996; at amount paid in 45,688 595
Deferred compensation (857) (526)
Deficit accumulated during the development stage (23,237) (18,150)
-------- --------
Total stockholders' equity (net capital deficiency) 21,594 (10,368)
-------- --------
Total liabilities and stockholders' equity $ 24,190 $ 3,964
======== ========
</TABLE>
(1) The information in this column was derived from the Company's audited
financial statements as of December 31, 1996.
See accompanying notes to financial statements.
3
<PAGE>
CARDIMA, INC.
STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
<TABLE>
<CAPTION>
Three months ended Six months ended
June 30, June 30,
------------------ ------------------
1997 1996 1997 1996
-------- ------- ------- --------
<S> <C> <C> <C> <C>
Net sales $ 319 $ 280 $ 536 $ 412
Cost of goods sold 457 393 831 777
------- ------- ------- -------
Gross profit (138) (113) (295) (365)
Operating expenses:
Research and development 1,059 632 1,869 1,228
Selling, general and administrative 1,646 925 2,977 1,659
------- ------- ------- -------
Total operating expenses 2,705 1,557 4,846 2,887
------- ------- ------- -------
Operating loss (2,843) (1,670) (5,141) (3,252)
Interest and other income 110 48 135 112
Interest expense (28) (5) (81) (7)
------- ------- ------- -------
Net loss $(2,761) $(1,627) $(5,087) $(3,147)
======= ======= ======= =======
Net loss per share $ (1.21) $ (1.91)
======= =======
Shares used in computing net loss per share 2,277 2,670
======= =======
Pro forma net loss per share $ (0.25) $ (0.50)
======= =======
Shares used in computing pro forma net loss
per share 6,431 6,313
======= =======
</TABLE>
See accompanying notes to financial statements
4
<PAGE>
CARDIMA, INC.
STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
<TABLE>
<CAPTION>
SIX MONTHS
ENDED JUNE 30,
-----------------------
1997 1996
--------- ---------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss ($5,087) ($3,147)
Adjustments to reconcile net loss to net cash provided by operations:
Depreciation and amortization 277 129
Amortization of deferred compensation 101 7
Changes in operating assets and liabilities:
Accounts receivable (93) (87)
Inventories (209) (117)
Other current assets (70) (232)
Restricted cash 20 -
Other assets 475 -
Accounts payable (525) 98
Accrued compensation 60 62
Other current liabilities 42 6
Deferred rent (25) 33
--------- ---------
Net cash used in operating activities (5,034) (3,248)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (717) (91)
--------- ---------
Net cash used in investing activities (717) (91)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments under capital leases (210) (143)
Decrease in notes payable (1,674) -
Net proceeds from issuance of preferred stock 13,442 3,559
Net proceeds from sale of common stock 13,765 2
--------- ---------
Net cash provided by financing activities 25,323 3,418
--------- ---------
NET INCREASE IN CASH AND CASH EQUIVALENTS 19,572 79
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 907 2,993
--------- ---------
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 20,479 $ 3,072
========= =========
</TABLE>
5
<PAGE>
CARDIMA, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 1997
(Unaudited)
1. BASIS OF PRESENTATION
The accompanying unaudited financial statements have been prepared by the
Company according to the rules and regulations of the Securities and Exchange
Commission for interim financial information and in accordance with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they
do not include all of the financial information and footnotes required by
generally accepted accounting principles for complete financial statements. In
the opinion of management, all adjustments (consisting of normal recurring
adjustments) considered necessary for a fair presentation have been included.
The operating results for the three month and six month period ended June
30, 1997 are not necessarily indicative of the results that may be expected for
the fiscal year ending December 31, 1997. The accompanying financial
statements should be read in conjunction with the audited financial statements
and notes thereto included in the Company's Form S-1 (No. 333-23209) dated March
13, 1997.
2. BALANCE SHEET COMPONENT
<TABLE>
<CAPTION>
Certain balance sheet components are as follows: (In thousands)
(Unaudited)
June 30, Dec. 31,
1997 1996
-------- --------
<S> <C> <C>
Inventories:
Raw materials $ 187 $ 145
Work-in-process 168 131
Finished goods 231 101
-------- --------
$ 586 $ 377
======== ========
Property and equipment:
Equipment $ 3,063 $ 2,008
Leasehold improvements 99 93
-------- --------
$ 3,162 $ 2,101
Less accumulated depreciation 975 701
-------- --------
$ 2,187 $ 1,400
======== ========
</TABLE>
6
<PAGE>
NOTES TO FINANCIAL STATEMENT (continued)
(Unaudited)
3. INITIAL PUBLIC OFFERING
In June 1997, the Company completed an initial public offering of 2,275,000
shares of Common Stock at an initial price to the public of $7.00 per share,
resulting in net proceeds to the Company (after deducting underwriting discounts
and commissions and offering expenses) of approximately $13.8 million.
4. NET LOSS PER SHARE
Net loss per share is computed using the weighted average number of common
shares outstanding. Common equivalent shares are excluded from the computation
as their effect is antidilutive, except that, pursuant to the Securities and
Exchange Commission ("SEC") Staff Accounting Bulletins, common and common
equivalent shares issued during the 12-month period prior to the filing of a
registration statement in connection with the Company's initial public offering
at prices below the public offering price of $7.00 have been included in the
calculation as if they were outstanding for all periods presented through June
30, 1997 (using the treasury stock method for stock options at the estimated
public offering price).
Pro forma net loss per share for the three months and six months ended June
30, 1997 and 1996 has been computed as described above and also gives effect to
the conversion of convertible preferred shares not included above that
automatically converted upon completion of the Company's initial public offering
(using the "if converted" method) from original date of issuance. For the three
and six months ended June 30, 1997, pro forma net loss per share was ($0.58) and
($0.91) per share, respectively.
In February 1997, the Financial Accounting Standards Board issued Statement
No. 128, "Earnings per share", which is required to be adopted on December 31,
1997. At that time, the Company will be required to change the method currently
used to compute earnings per share and to restate all prior periods. The impact
on earnings per share for the three and six months ended June 30, 1997 and 1996
is not expected to be material.
7
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
This Form 10-Q, including management's discussion and analysis of financial
condition and results of operations, contains "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934, including, without limitation,
statements regarding regulatory approvals, operating results and capital
requirements. Except for historical information, the matters discussed in this
Form 10-Q, are forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
projected. Such factors include the Company's ability to conduct successful
clinical trials, obtain timely regulatory approvals and gain acceptance from the
marketplace for its products, as well as the risk factors discussed below in
"Factors Affecting Future Results" and those listed from time to time in the
Company's SEC reports. The Company assumes no obligation to update the forward-
looking statements included in this Form 10-Q.
OVERVIEW
Since its incorporation in November 1992, Cardima has been engaged in the
design, research and development, manufacturing and testing of microcatheter
systems for the mapping (diagnosing) and ablation (treating) of cardiac
arrhythmias. The Company has a limited history of operations and has
experienced significant operating losses since inception. The Company expects
that its operating losses will continue for the foreseeable future as the
Company continues to invest substantial resources in product development,
preclinical and clinical trials, obtaining regulatory approval, sales and
marketing and manufacturing.
To date, Cardima has generated limited revenues which, until January 1997,
have primarily been in Europe and Japan, from sales of the Cardima Pathfinder
and Tracer for diagnosing Ventricular Tachycardia (VT) and the Cardima
Pathfinder AF for diagnosing Atrial Fibrillation (AF). The Company has
obtained the right to affix the CE mark to its Cardima Pathfinder, Tracer and
Cardima Pathfinder AF microcatheter systems, permitting the Company to market
these products in the member countries of the EU. The Company's international
sales are made through distributors who sell the Company's products to
physicians and hospitals, although the Company is currently evaluating the
establishment of a direct sales force in certain key European countries. In
January 1997, the Company received a 510(k) clearance in the United States and
began to market and sell the Cardima Pathfinder system for diagnosing VT. As a
result, a significant portion of the Company's revenues in the six months
ended June 30, 1997 were from sales in the United States. In order to begin
shipping the Tracer microcatheter systems for diagnosing VT or the Cardima
Pathfinder AF for diagnosing AF in the United States, the Company will need to
receive 510(k) clearance for these products from the FDA. The Company has
submitted a 510(k) premarket notification for the Cardima Pathfinder AF and
intends to seek 510(k) clearance for its other diagnostic products, including
the Cardima Pathfinder 1.5 Fr. and Tracer products. The Company will be
required to conduct clinical trials, demonstrate safety and effectiveness, and
obtain PMA approval from the FDA in order to sell any of the Company's
products designed for treatment of AF or VT in the United States.
Specifically, PMA approval will be required prior to the introduction in the
United States of the Cardima Pathfinder AF microcatheter system for treatment
of AF or Tracer VT microcatheter system for treatment of VT. In January 1997,
the Company submitted an IDE for the Cardima Pathfinder AF microcatheter
system for diagnosing and treatment of AF and in June 1997 received
conditional approval from the FDA to begin a Phase I feasibility study for
8
<PAGE>
diagnosing AF. The Company has recently begun Phase I clinical trials for its
Cardima Pathfinder AF microcatheter system and expects to file an additional
IDE and begin clinical trials for its Tracer VT microcatheter system in the
second half of 1997.
RESULTS OF OPERATIONS
Net Sales
Net sales for the quarter ended June 30, 1997 increased 14% to $319,000
from $280,000 in the same period in 1996. Net sales for the six month period
ended June 30, 1997 increased 30% to $536,000 from $412,000 in the same period
in 1996. Each of these increases is due primarily to U.S. sales of the Cardima
Pathfinder line of microcatheters for diagnosis of VT following FDA clearance in
January 1997.
Cost of Good Sold
Cost of goods sold primarily includes raw materials costs, catheter
fabrication costs and system assembly and test costs. Cost of goods sold for
the quarter ended June 30, 1997 increased 16% to $457,000 from $393,000 in the
same period in 1996. Cost of goods sold for the six month period ended June 30,
1997 increased 7% to $831,000 from $777,000 in the same period in 1996. Each of
these increases is due primarily to the growth in the Company's manufacturing
operations to support domestic product sales and low initial production volumes.
Research and Development Expenses
Research and development expenses for the quarter ended June 30, 1997
increased 68% to $1,059,000 from $632,000 in the same period in 1996. Research
and development expenses for the six month period ended June 30, 1997 increased
52% to $1,869,000 from $1,228,000 in the same period in 1996. Each of these
increases is due primarily to staff additions and associated expenses in
research and development, clinical and regulatory areas incurred as the
Company adds resources to meet program goals and clinical objectives.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the quarter ended June 30,
1997 increased 78% to $1,646,000 from $925,000 in the same period in 1996.
Selling, general and administrative expenses for the six month period ended June
30, 1997 increased 79% to $2,977,000 from $1,659,000 in the same period in 1996.
The increases in selling expenses are due primarily to expansion of the
Company's U.S. sales force and the commitment of additional resources to support
the Company's European sales efforts. The increases in general and
administrative expenses are due primarily to additional staffing and expenses to
meet the growth of the Company and expenses related with the requirements of a
public company. The increases in marketing expenses were due primarily to
additional staffing, marketing materials and programs to meet new product
introductions.
9
<PAGE>
Interest and Other Income
Interest and other income for the quarter ended June 30, 1997 increased
129% to $110,000 from $48,000 in the same period in 1996. Interest income for
the six month period ended June 30, 1997 increased 21% to $135,000 from
$112,000 in the same period in 1996. Each of these increases is due
primarily to larger cash and cash equivalent balances as a result of the
Company's IPO.
Interest Expense
Interest expense for the quarter ended June 30, 1997 increased to $28,000
from $5,000 in the same period in 1996. Interest expense for the six month
period ended June 30, 1997 increased to $81,000 from $7,000 in the same period
in 1996. Each of these increases is due primarily to higher borrowing levels
during periods prior to the Company's initial public offering.
LIQUIDITY AND CAPITAL RESOURCES
The Company has financed its operations to date principally through private
placements of equity securities, which had yielded net proceeds of $30.9 million
as of June 30, 1997, together with interest income on such proceeds, an initial
public offering of Common Stock in June 1997, which yielded net proceeds of
approximately $13.8 million, and equipment leases, which have totaled $1.9
million to acquire certain capital equipment. As of June 30, 1997, the Company
had approximately $20.7 million in cash and cash equivalents, of which $255,000
was restricted in order to secure letters of credit issued in connection with
the Company's facilities lease.
Net cash used in operating activities was approximately $5.0 million for
the six months ended June 30, 1997 and $3.2 million for the six months ended
June 30, 1996, resulting primarily from losses incurred during such periods.
Net cash used in investing activities was approximately $717,000 for the
six months ended June 30, 1997 and $91,000 for the six months ended June 30,
1996, attributable primarily to capital expenditures during such periods. Net
cash provided by financing activities was approximately $25.3 million for the
six months ended June 30, 1997, and $3.4 million for the six months ended June
30, 1996, resulting primarily from the Company's initial public offering
and the sale of equity securities in private placement transactions.
The Company's future liquidity and capital requirements will depend upon
numerous factors, including the progress of the Company's product development
efforts, the progress of the Company's clinical trials, actions relating to
regulatory matters, the costs and timing of expansion of product development,
manufacturing, sales and marketing activities, the extent to which the Company's
products gain market acceptance, and competitive developments. The Company
believes that available cash and cash generated from operations will be
sufficient to meet the Company's operating expenses and capital requirements at
least through the end of 1998. There can be no assurance, however, that the
Company will not require additional financing during that period, or that if
required, such additional financing will be available on terms acceptable to the
10
<PAGE>
Company, if at all. The Company may seek to raise additional funds through
public or private financing, collaborative relationships or other arrangements.
There can be no assurance that such additional funding, if needed, will be
available on terms acceptable to the Company, if at all. Furthermore, any
additional equity financing may be dilutive to stockholders, and debt financing,
if available, may involve restrictive covenants. Collaborative arrangements, if
necessary to raise additional funds, may require the Company to relinquish its
rights to certain of its technologies, products or marketing territories. The
failure of the Company to raise capital when needed would have a material
adverse effect on the Company's business, financial condition and results of
operations.
FACTORS AFFECTING FUTURE RESULTS
HISTORY OF LOSSES AND EXPECTATION OF SUBSTANTIAL FUTURE LOSSES
Since inception, the Company has experienced losses and expects to
experience substantial net losses for the foreseeable future. To date, sales of
its Cardima Pathfinder, Cardima Pathfinder AF and Tracer microcatheter systems
have been limited. The Company had net losses of approximately $5.2 million and
$7.8 million for 1995 and 1996, respectively, and $2.8 million for the three
months ended June 30, 1997 and $5.1 million for the six months ended June 30,
1997. As of June 30, 1997, the Company had an accumulated deficit of
approximately $23.2 million. The Company expects to incur substantial net
losses for the foreseeable future as a result of research and product
development, clinical trials, manufacturing, sales, marketing and other expenses
expected to be incurred as the Company further develops, tests and distributes
its microcatheter systems. The Company's limited operating history makes
accurate prediction of future operating results difficult or impossible. There
can be no assurance that the Company will ever generate substantial net sales or
achieve profitability. Failure by the Company to generate substantial revenues
or to reduce the research and development, marketing, and manufacturing expenses
below net sales would have a material adverse effect on the Company's business,
financial condition and results of operations.
NO ASSURANCE OF SAFETY AND EFFECTIVENESS; EARLY STAGE OF PRODUCT DEVELOPMENT
The Company is currently developing versions of its Cardima Pathfinder and
Tracer microcatheter systems for mapping AF and VT. To date, the Company has
completed only one clinical trial and has received 510(k) pre-market clearance
only with respect to its Cardima Pathfinder microcatheter system for venous
mapping of VT, including the Cardima Pathfinder microcatheter and Venaport
guiding catheter. While the Cardima Pathfinder AF microcatheter system for
mapping AF is currently being sold in certain foreign markets, the Company has
not received 510(k) clearance for sale of this product in the United States.
There can be no assurance that 510(k) clearance for the Cardima Pathfinder AF
mapping system will be obtained in a timely manner, or at all. Failure to
obtain such clearance on a timely basis would have a material adverse effect on
the Company's business, financial condition and results of operations.
The Company is in the early stage of developing, testing and obtaining
regulatory approval for its microcatheter systems designed for ablation of AF
and VT. The Company is currently developing the Cardima Pathfinder AF
microcatheter system for ablation of AF and the Tracer VT microcatheter system
for ablation of VT. The Company has not conducted any human clinical studies
using its microcatheter systems for the ablation of AF or VT. The Company is
required to obtain an Investigational Device Exemption ("IDE") from the FDA
prior to conducting human clinical trials of its microcatheter systems for
ablation. The Company recently filed an IDE for the Cardima Pathfinder AF
microcatheter system for mapping and ablation, which was conditionally approved
by the FDA for Phase I and consists of a feasibility study for AF mapping. The
Company has initiated the feasibility study for AF mapping, which
11
<PAGE>
is being conducted at Stanford University Hospital and Massachusetts General
Hospital. The FDA has not approved any studies for ablation, and the Company
will be required to submit the results of the Phase I mapping study prior to
conducting clinical studies for ablation. There can be no assurance that the
Company will successfully complete its Phase I study, that the results will
permit the Company to file an IDE for the ablation of AF or that the FDA will
approve any filed IDE for the ablation of AF. Except for the IDE relating to the
Cardima Pathfinder AF microcatheter system for mapping and ablation, which
resulted in the Company receiving conditional approval from the FDA for Phase I
clinical studies and under which a feasibility study has been initiated, the
Company has not filed IDEs or begun clinical trials for its microcatheter
systems under development for ablation. The Company must complete these clinical
trials, if initiated, prior to the filing of a Pre-market Approval Application
("PMA"), and must receive PMA approval prior to marketing such products for
ablation in the United States. Clinical trials of the Company's microcatheter
systems will require substantial financial and management resources of the
Company and the completion of such trials will take several years. There can be
no assurance that necessary IDEs will be granted by the FDA, that human clinical
trials, if initiated, will be completed or that these clinical studies will
validate the results of the Company's pre-clinical studies or demonstrate that
such products are safe and effective. In addition, the clinical trials may
identify significant technical or other obstacles to be overcome prior to
obtaining necessary regulatory approvals or market acceptance. The failure of
the Company to initiate and complete clinical trials, demonstrate product safety
and clinical effectiveness, or obtain regulatory approval for the Cardima
Pathfinder AF for AF ablation or the Tracer VT for VT ablation would have a
material adverse effect on the Company's business, financial condition and
results of operations.
UNCERTAINTY OF PRODUCT AND PROCEDURE ACCEPTANCE
The Company's microcatheter systems represent a novel approach to the
mapping and ablation of AF and VT. Acceptance of the Company's products and
procedures by physicians, patients and health care payors will be necessary in
order for the Company to be successful. The Company's microcatheter systems for
the mapping and ablation of AF and VT are new technologies that must compete
with more established treatments such as drugs, external electrical
cardioversion and defibrillation, implantable defibrillators, purposeful
destruction of the Atrio-Ventricular ("AV") node followed by implantation of a
pacemaker, and open heart surgery. It is likely that physicians will not
recommend the use of the Company's microcatheter systems unless they conclude,
based on clinical data and other factors, that these systems provide a safe,
effective and cost-efficient alternative to established or emerging approaches
to the mapping and ablation of AF and VT. Except for the Cardima Pathfinder
microcatheter system for mapping VT, none of the products currently being
developed by Cardima for the mapping and ablation of AF and VT has obtained
regulatory clearance or approval in the United States. Even if the Company's
products are successfully developed and the required regulatory clearance or
approval is obtained, there can be no assurance that such products and the
associated procedures will ultimately gain any significant degree of market
acceptance. Since the Company's sole product focus is to design and market
microcatheter systems to map and ablate AF and VT, the failure to successfully
commercialize these systems would have a material and adverse affect on the
Company's business, financial condition and results of operations.
Risks Regarding Products and Procedures Designed for Mapping and Ablation
of AF. Cardima is developing its Cardima Pathfinder AF microcatheter system for
mapping and ablation of AF. Currently, there is considerable clinical debate
about the need for mapping AF prior to ablation, and no mapping is performed
during the open heart surgical maze procedure. However, the Company believes
that mapping
12
<PAGE>
prior to ablation may be useful to identify different segments of the AF
population, each of which could require slightly different mapping and ablation
procedures. For example, some electrophysiologists believe most AF patients will
need to be mapped and ablated in both the left and right atria, while others
believe only the right atrial intervention is warranted. Market acceptance of
this product for mapping will depend largely on a determination that there is a
clinical need for diagnostic mapping prior to ablation of AF. The Cardima
Pathfinder AF ablation procedure requires the use of RF energy in the right and
left atria to produce lesions. In general, the use of RF energy in the left
atrium has the potential to create blood clots, which could travel through the
vasculature to the brain and cause a stroke. Consequently, physicians may not
recommend this procedure, in which event the Cardima Pathfinder AF would be
unlikely to gain market acceptance. The failure of the Company to complete
development of the Cardima Pathfinder AF or to gain regulatory approval,
demonstrate safety, clinical effectiveness or cost effectiveness, gain wide
market acceptance or successfully commercialize the Cardima Pathfinder AF for
the mapping and ablation of AF would have a material adverse effect on the
Company's business, financial condition and results of operations.
Risks Regarding Products and Procedures Designed for Mapping and Ablation
of VT. The Cardima Pathfinder and Tracer microcatheter systems for VT mapping
are designed for use inside the vasculature of the heart wall and to provide
access to the vasculature of the heart through the venous system. To achieve
market acceptance, the Company will need to demonstrate the safety, clinical
effectiveness and cost effectiveness of the Cardima Pathfinder and Tracer
microcatheter systems for VT mapping, of which there can be no assurance. In
addition, electrophysiologists will need to be specially trained to perform this
procedure, which may further impede market acceptance. There can be no
assurance that the Cardima Pathfinder or Tracer microcatheter systems for VT
mapping will ever achieve market acceptance, or in the case of the Tracer
microcatheter system, be cleared for marketing by U.S. Regulatory authorities,
or be successfully commercialized in the United States or internationally. The
inability of the Company to gain wide market acceptance or successfully
commercialize the Cardima Pathfinder and Tracer microcatheter systems for VT
mapping would have a material adverse effect on the Company's business,
financial condition and results of operations.
The Company's Tracer VT microcatheter system is being developed for
ablation of VT using RF energy, which could cause damage to the arteries and
veins of the heart, potentially leading to myocardial infarction and even death.
Consequently, physicians may not recommend this procedure, in which event the
Tracer VT would be unlikely to gain market acceptance. Failure of the Company
to gain market acceptance or successfully commercialize the Tracer VT would have
a material adverse effect on the Company's business, financial condition and
results of operations.
FLUCTUATIONS IN OPERATING RESULTS
The Company's results of operations may fluctuate significantly from
quarter to quarter or year to year depending upon a number of factors, including
actions relating to regulatory matters, progress of pre-clinical and clinical
trials, the extent to which the Company's products gain market acceptance, the
scale-up of manufacturing capabilities, the expansion of sales and marketing
activities, competition, the timing of new product introductions by the Company
or its competitors and the ability of the Company to market its products
successfully in the United States and internationally. Although the Cardima
Pathfinder and Tracer microcatheter systems are labeled for single use only, the
Company is aware that some physicians in international markets are reusing these
products. Reuse of the Company's microcatheter systems would reduce revenues
from product sales and could have a material adverse effect on future
performance
13
<PAGE>
and periodic operating results. Due to such fluctuations in operating results,
period to period comparisons of the Company's revenues and operating results are
not necessarily meaningful and should not be relied upon as indicators of likely
future performance or annual operating results.
NO ASSURANCE OF OBTAINING REQUIRED REGULATORY APPROVALS; GOVERNMENT REGULATION
The pre-clinical and clinical testing, manufacturing, labeling,
distribution and promotion of the Company's products are subject to extensive
and rigorous government regulation in the United States and other countries.
Noncompliance with applicable requirements can result in enforcement actions by
the FDA including, among other things, fines, injunctions, civil penalties,
recall or seizure of products, refusal of the FDA to grant pre-market clearances
or approvals, withdrawal of marketing approvals and criminal prosecution. Any
such action would have a material adverse effect on the Company's business,
financial condition and results of operations.
The Company is prohibited from marketing its products in the United States
unless it obtains 510(k) clearance or PMA approval from the FDA. The Company
believes that it usually takes from four to twelve months from submission to
obtain 510(k) clearance, but that it can take longer. The Cardima Pathfinder
microcatheter system for mapping VT has received 510(k) clearance. The Company
believes that its current mapping products will also be eligible for 510(k)
clearance, and has submitted 510(k) pre-market notifications for the Cardima
Pathfinder AF and Cardima Pathfinder 1.5 Fr. and intends to seek 510(k)
clearance for the Tracer products. These submissions may need to include
clinical trial data. There can be no assurance, however, that any of these
products will receive 510(k) clearance in a timely fashion, if at all. Delays
in market introduction resulting from the 510(k) clearance process could have
a material adverse effect on the Company's business, financial condition and
results of operations.
The Company will be required to seek PMA approval for its ablation
products, including the Cardima Pathfinder AF and the Tracer VT microcatheters
for ablation. The process of obtaining PMA approval is much more costly,
lengthy and uncertain than the 510(k) clearance process. The Company believes
that the FDA's review of a PMA application after filing can last from one to
three years, or even longer. In order to prepare a PMA application, the Company
will be required to complete clinical trials to demonstrate the safety and
effectiveness of these products. To date, the Company has not conducted any
human clinical studies using its microcatheter systems for the ablation of AF or
VT. In January 1997, the Company submitted an IDE for the Cardima Pathfinder AF
microcatheter system for mapping and ablation of AF and received conditional
approval from the FDA to begin its Phase I feasibility study for mapping AF. In
July 1997, the Company initiated its Phase I feasibility study at Stanford
University Hospital and Massachusetts General Hospital. The FDA has not
approved any clinical studies for ablation, and the Company will be required to
submit the results of the Phase I mapping study prior to conducting clinical
studies for ablation. The Company expects to file an additional IDE and begin
its clinical trials for the Tracer VT microcatheter system in the second half of
1997. There can be no assurance that any clinical study that the Company
proposes will be permitted by the FDA, will be completed or, if completed, will
provide data and information that supports additional clinical investigations of
the type necessary to obtain PMA approval. The Company expects that a PMA
application will not be submitted for at least two years, if at all. No
assurance can be given that the Company will ever be able to obtain PMA approval
for any of its ablation products. Failure of the Company to obtain timely PMA
approval would have a material adverse effect on the Company's business,
financial condition and results of operations.
14
<PAGE>
The Company is subject to periodic inspection by the FDA and the California
Department of Health Services, and must comply with various other regulatory
requirements that apply to medical devices marketed in the United States,
including labeling regulations, the Quality System Regulation ("QSR"), the
Medical Device Reporting regulation (which requires that a manufacturer report
to the FDA certain types of adverse events involving its products), and the
FDA's prohibitions against promoting approved products for unapproved ("off-
label") uses. The Company's failure to comply with applicable regulatory
requirements could result in enforcement action by the FDA, which could have a
material adverse effect on the Company's business, financial condition and
results of operations.
Sales of medical devices outside the United States are subject to
international regulatory requirements that vary from country to country. The
time required for approval varies from country to country and may be longer or
shorter than the time required in the United States. The Company has obtained
the requisite approvals by means of the CE mark to sell the Cardima Pathfinder,
Cardima Pathfinder 1.5 Fr., Cardima Pathfinder AF, Tracer and Venaport for
mapping in the European Union ("EU") and Australia, to sell the Cardima
Pathfinder, Cardima Pathfinder 1.5 Fr., Cardima Pathfinder AF and Tracer in
Japan and to sell the Cardima Pathfinder, Tracer and Venaport in Canada. The
Company plans to commence clinical trials in the EU, Canada and Japan for its
ablation products, including certification to enable CE marking. There can be
no assurance the Company will be successful in obtaining such approvals.
Failure to receive approval to affix the CE mark would prohibit the Company from
selling these products in member countries of the EU, and would require
significant delays in obtaining individual country approvals. No assurance can
be given that such approvals will ever be obtained. In such event, the
Company's business, financial condition and results of operations would be
materially and adversely affected.
RAPID TECHNOLOGICAL CHANGE; SIGNIFICANT COMPETITION
The medical device industry is characterized by rapid and significant
technological change. Accordingly, the Company's success will depend in part on
its ability to respond quickly to medical and technological changes, including
changes in the capital equipment with which the Company's microcatheter systems
are designed to be compatible. Product development involves a high degree of
risk, and there can be no assurance that the Company's new product development
efforts will result in any commercially successful products. Failure by the
Company to respond to and develop new technologies could have a material adverse
effect on the Company's business, financial condition and results of operations.
The Company's microcatheter systems for the mapping and ablation of AF and
VT are new technologies that must compete with more established treatments such
as drugs, external electrical cardioversion and defibrillation, implantable
defibrillators, purposeful destruction of the AV node followed by implantation
of a pacemaker, and open heart surgery. In the market for cardiac mapping and
ablation devices, the Company believes that the primary competitive factors are
safety, effectiveness, ease of use and overall system cost. In addition, the
length of time required for products to be developed and to receive regulatory
and, in some cases, reimbursement approval are important competitive factors.
Several of the Company's competitors are currently marketing and selling
catheters in the United States and internationally that map and ablate a type of
arrhythmia known as supraventricular tachycardia ("SVT"). In addition, several
competitors are also developing new approaches and new products for the mapping
and/or ablation of AF and VT. These approaches include mapping systems using
contact mapping, single-point spatial mapping and non-contact, multi-site
electrical mapping technologies, and
15
<PAGE>
ablation systems using RF, ultrasound, microwave, laser and cryoablation
technologies. In addition, companies are developing surgical procedures that
could potentially be used by physicians to perform the open heart surgical maze
procedure for the treatment of AF in a minimally invasive manner. If any of
these new approaches or new products prove to be safe and effective, the
Company's products could be rendered noncompetitive or obsolete, which could
have a material adverse effect on the Company's business, financial condition
and results of operations.
Many of the Company's competitors have an established presence in the field
of interventional cardiology and electrophysiology, including Boston Scientific,
C.R. Bard, Inc., Johnson & Johnson, through its Cordis division, St. Jude
Medical, Inc., through its Daig division, and Medtronic, Inc. These competitors
have substantially greater financial and other resources than the Company,
including larger research and development staffs and more experience and
capabilities in conducting research and development activities, testing products
in clinical trials, obtaining regulatory approvals, and manufacturing, marketing
and distributing products. In addition, other companies are developing
proprietary systems for the diagnosis and/or treatment of cardiac arrhythmias,
including Biosense, Inc., Cardiac Pathways, Inc. and Endocardial Solutions, Inc.
Other companies develop, market and sell alternative approaches to the treatment
of AF and VT, including Guidant Corporation, Medtronic, Inc., and Ventritex,
Inc., a subsidiary of St. Jude, Inc., the leading manufacturers of implantable
defibrillators. There can be no assurance that the Company will succeed in
developing and marketing technologies and products that are more clinically
effective and cost-effective than the more established treatments or the new
approaches and products being developed and marketed by its competitors.
Furthermore, there can be no assurance the Company will succeed in developing
new technologies and products that are available prior to its competitors'
products. Failure of the Company to demonstrate the competitive advantages of
its products would have a material adverse effect on the Company's business,
financial condition and results of operations.
FUTURE ADDITIONAL CAPITAL REQUIREMENTS; NO ASSURANCE FUTURE CAPITAL WILL BE
AVAILABLE
The Company's future liquidity and capital requirements will depend on
numerous factors, including the progress of the Company's clinical research and
product development programs: the receipt of, and the time required to obtain,
regulatory clearances and approvals; the costs and timing of expansion of
product development, manufacturing and sales and marketing activities; the
extent to which the Company's products gain market acceptance; competitive
developments; and other factors. The timing and amount of such capital
requirements cannot be accurately predicted. In addition, if unforeseen
difficulties arise in the course of developing its products, performing clinical
trials, obtaining necessary regulatory clearances and approvals or other aspects
of the Company's business, the Company may be required to invest greater-than-
anticipated funds. As a consequence, the Company may be required to raise
additional funds through public or private debt or equity financings,
collaborative relationships, bank facilities or other arrangements. If
additional financing is needed, there can be no assurance that it will be
available on terms acceptable to the Company, if at all. Any additional equity
financing may be dilutive to stockholders, and debt financing, if available, may
involve restrictive covenants.
DEPENDENCE ON PATENTS AND PROPRIETARY AND LICENSED TECHNOLOGY; RISK OF PATENT
INFRINGEMENT
The Company's success will depend in part on its ability to obtain patent
protection for its products and processes, to preserve its trade secrets,
trademarks, copyrights and to operate without infringing or violating the
proprietary rights of others. The Company's strategy is to actively pursue
16
<PAGE>
patent protection in the United States and foreign jurisdictions for technology
that it believes to be proprietary and that offers a potential competitive
advantage for its products. The patent positions of medical device companies,
including the Company, are uncertain and involve complex and evolving legal and
factual questions. The coverage sought in a patent application either can be
denied or significantly reduced before or after the patent is issued. In
addition, the U.S. patent laws were recently amended to exempt physicians, other
health care professionals and affiliated entities from infringement liability
for medical and surgical procedures performed on patients. The Company cannot
predict whether this amendment might have a material adverse effect on the
Company's ability to protect its proprietary methods and procedures.
In addition, there can be no assurance that competitors will not seek to
apply for and obtain patents that will prevent, limit or interfere with the
Company's ability to make, use or sell its products either in the United States
or internationally. Further, the laws of certain foreign countries do not
protect the Company's intellectual property rights to the same extent as do the
laws of the United States. In addition to patents, trademarks and copyrights,
the Company relies on trade secrets and proprietary know-how to compete, which
it seeks to protect, in part, through appropriate confidentiality and
proprietary information agreements. There can be no assurance that proprietary
information or confidentiality agreements with employees, consultants and others
will not be breached, that the Company will have adequate remedies for any
breach, or that the Company's trade secrets will not otherwise become known to,
or independently developed by, competitors. The Company also relies on certain
license agreements through which it licenses certain technology from others,
including technology of Target Therapeutics, Inc., a subsidiary of Boston
Scientific Corporation, ("Target") that is integrated into the Company's
microcatheter systems for mapping and ablation. The Company has also licensed a
proprietary surface coating material used on certain of its catheters. There
can be no assurance that these licenses will continue to be available to the
Company. The loss of or inability to maintain any of these licenses could
result in delays in commercial shipments by the Company until equivalent
technology could be developed internally or identified, licensed and integrated,
which would have a material adverse effect on the Company's business, financial
condition and results of operations.
Although the Company has not received any significant letters from others
threatening to enforce intellectual property rights against the Company, there
can be no assurance that the Company will not become subject to patent
infringement claims or litigation, to interference proceedings in the USPTO to
determine the priority of inventions or to oppositions to patent grants in
foreign jurisdictions. An adverse determination in litigation, interference or
opposition proceedings to which the Company may become a party could subject the
Company to significant liabilities to third parties, require disputed rights to
be licensed from third parties or require the Company to cease using such
technology. Under the Company's license agreement with Target, the Company is
not indemnified against claims brought by third parties alleging infringement of
patent rights. Consequently, the Company could bear the liability resulting
from such claims. There can be no assurance that the Company will have the
financial resources to protect and defend its intellectual property, as such
defense is often costly and time consuming. Failure of the Company to protect
its patent rights, trade secrets, know-how or other intellectual property could
have a material adverse effect on the Company's business, financial condition
and results of operations.
The validity and breadth of claims in medical technology patents involve
complex legal and factual questions and, therefore, may be highly uncertain.
There can be no assurance that any issued patent or patents based on pending
patent applications or any future patent application will exclude competitors or
provide competitive advantages to the Company, that any of the Company's patents
or
17
<PAGE>
patents in which it has licensed rights will be held valid if subsequently
challenged or that others will not claim rights in or ownership of the patents
and other proprietary rights held or licensed by the Company. There can be no
assurance that others have not developed or will not develop similar products,
duplicate any of the Company's products or design around any patents issued to
or licensed by the Company or that may be issued in the future to the Company.
Since patent applications in the United States are maintained in secrecy until
patents issue, the Company cannot be certain that others were not the first to
file applications for inventions covered by the Company's pending patent
applications, nor can the Company be certain that it will not infringe any
patents that may be issued to others on such applications. The Company
periodically reviews the scope of patents of which it is aware. Although Cardima
does not believe that it infringes patents known to the Company, the question of
patent infringement involves complex legal and factual issues and there can be
no assurance that any conclusion reached by the Company regarding infringement
will be consistent with the resolution of any such issues by a court.
INFLUENCE OF BOSTON SCIENTIFIC CORPORATION/TARGET THERAPEUTICS, INC.
As of August 12, 1997, Target beneficially owned approximately 9.5% of the
Company's outstanding Common Stock. In April 1997, Boston Scientific completed
the acquisition of Target, by merging Target with a wholly-owned subsidiary. As
a result of the acquisition, Boston Scientific exercises control over a
significant portion (approximately 9.5%) of the Company's outstanding Common
Stock. Accordingly, Boston Scientific may be able to exercise influence over the
business and financial affairs of the Company. Boston Scientific develops,
markets and sells cardiac electrophysiology products that compete directly with
the microcatheter products being developed by the Company. There can be no
assurance that Boston Scientific will not take actions or engage in activities
that could have a material adverse effect on the Company's business, financial
condition or results of operations.
The Company and Target have entered into a license agreement (the "Target
License Agreement"), pursuant to which Target has granted the Company an
exclusive license (the "Target License") under certain issued United States
patents to certain technologies upon which the Company's products are based. The
Target License covers the diagnosis and treatment of electrophysiological
disorders in areas other than the central nervous system. The Target License
will terminate upon the expiration or invalidation of all claims under the
underlying patents. In addition, the Company has obtained a non-exclusive
license to use Target's technology, provided it has made a substantial
improvement of such technology, for the diagnosis or treatment of diseases of
the heart, other than using balloon angioplasty. Under the Target License
Agreement, Cardima has granted Target an exclusive, royalty-free license to use
any technology developed by Cardima prior to May 1996 in the fields of
neurology, interventional neuroradiology, interventional radiology, diagnosis
and treatment of male and female reproductive disorders and vascular
prostheses. The Target License Agreement imposes various commercialization,
sublicensing, insurance, royalty, product liability, indemnification, non-
competition and other obligations on the Company. Failure by the Company to
comply with certain of these requirements could result in a termination of the
Target License. The loss of the Company's exclusive rights to the Target-based
microcatheter technology would have a material adverse effect on the Company's
business, financial condition and results of operations.
RISKS ASSOCIATED WITH INTERNATIONAL SALES
International sales have accounted for a significant portion of the
Company's revenues to date and will continue to account for a significant
portion of the Company's revenues for the foreseeable future. A
18
<PAGE>
number of risks are inherent in international transactions. International sales
may be limited or disrupted by the imposition of government controls, export
license requirements, economic or political instability, trade restrictions,
changes in tariffs or difficulties in staffing and management. Additionally,
although the Company's sales are denominated in U.S. dollars, Cardima's
business, financial condition and results of operations may be adversely
affected by fluctuations in currency exchange rates as well as increases in duty
rates and difficulties in obtaining export licenses. The financial condition,
expertise and performance of the Company's international distributors and any
future international distributors could affect sales of the Company's products
internationally and could have a material adverse effect on the Company's
business, financial condition and results of operations. The international
nature of the Company's business also subjects it and its representatives,
agents and distributors to laws and regulations of the international
jurisdictions in which they operate or in which the Company's products may be
sold. The regulation of medical devices in a number of such jurisdictions,
particularly in the EU, continues to develop, and there can be no assurance that
new laws or regulations will not have a material adverse effect on the Company's
business, financial condition and results of operations. Foreign regulatory
agencies often establish product standards different from those in the United
States and any inability to obtain foreign regulatory approvals on a timely
basis could have a material adverse effect on the Company's international
business and its financial condition and results of operations. In addition, the
laws of certain foreign countries do not protect the Company's intellectual
property rights to the same extent as do the laws of the United States. There
can be no assurance that the Company will be able to successfully commercialize
any of its current microcatheter products, including the Cardima Pathfinder and
Tracer microcatheter systems, or any future product in any foreign market.
UNCERTAINTY RELATED TO THIRD-PARTY REIMBURSEMENT
U.S. health care providers, including hospitals and physicians, that
purchase medical devices generally rely on third-party payors, principally
federal Medicare, state Medicaid and private health insurance plans, to
reimburse all or a part of the costs and fees associated with the procedures
performed using these devices. The Company's success will depend upon, among
other things, the ability of health care providers to obtain satisfactory
reimbursement from third-party payors for medical procedures in which the
Company's microcatheter systems are used. Third-party payors may deny
reimbursement if they determine that a prescribed device has not received
appropriate regulatory clearances or approvals, is not used in accordance with
cost-effective treatment methods as determined by the payor, or is experimental,
unnecessary or inappropriate. If FDA clearance or approval is received, third-
party reimbursement would also depend upon decisions by the United States Health
Care Financing Administration for Medicare, as well as by individual health
maintenance organizations, private insurers and other payors. Reimbursement
systems in international markets vary significantly by country and by region
within some countries, and reimbursement approvals may be obtained on a country-
by-country basis. Many international markets have government managed health care
systems that control reimbursement for new devices and procedures. In most
markets, there are private insurance systems as well as government managed
systems. There can be no assurance that reimbursement for the Company's products
will be available or, if available, that such reimbursement will be available in
sufficient amounts in the United States or in international markets under either
government or private reimbursement systems, or that physicians will support and
advocate reimbursement for procedures using the Company's products. Failure by
hospitals and other users of the Company's products to obtain reimbursement from
third-party payors or changes in government and private third-party payor
policies toward reimbursement for procedures employing the Company's products
would have a material adverse effect on the
19
<PAGE>
Company's business, financial condition and results of operations. Moreover, the
Company is unable to predict what additional legislation or regulation, if any,
relating to the heath care industry or third-party coverage and reimbursement
may be enacted in the future, or what effect such legislation or regulation
would have on the Company.
LIMITED MANUFACTURING EXPERIENCE; SCALE-UP RISK; NEED TO COMPLY WITH UNITED
STATES MANUFACTURING STANDARDS; DEPENDENCE ON KEY SUPPLIERS
The Company has only limited experience in manufacturing its microcatheter
systems. The Company currently manufactures its microcatheter systems in limited
quantities for U.S. and international sales and for pre-clinical and clinical
trials. The Company has no experience manufacturing its products in the volumes
that will be necessary for the Company to achieve significant commercial sales,
and there can be no assurance that reliable, high-volume manufacturing capacity
can be established or maintained at commercially reasonable costs. The Company
has recently increased the number of microcatheters manufactured and expects
that, if U.S. sales for the Cardima Pathfinder microcatheter system increase or
if the Company receives FDA clearance or approvals for other products, it will
need to expend significant capital resources and develop manufacturing expertise
to establish large-scale manufacturing capabilities. Manufacturers often
encounter difficulties in scaling up production of new products, including
problems involving production yields, quality control and assurance, component
supply shortages, shortages of qualified personnel, compliance with FDA
regulations, and the need for further FDA approval of new manufacturing
processes. In addition, the Company believes that substantial cost reductions in
its manufacturing operations will be required for it to commercialize its
microcatheter systems on a profitable basis. Any inability of the Company to
establish and maintain large-scale manufacturing capabilities would have a
material adverse effect on the Company's business, financial condition and
results of operations.
The Company's manufacturing facilities are subject to periodic inspection
by regulatory authorities, and its operations must either undergo QSR compliance
inspections conducted by the FDA or receive an FDA exemption from such
compliance inspections in order for the Company to be permitted to produce
products for sale in the United States. The Company's facilities and
manufacturing processes have recently successfully undergone a combined
inspection by the FDA and by the State of California and an annual reinspection
by TUV. The Company has demonstrated compliance with ISO 9001 (EN 46001) quality
standards, as well as compliance with 93/42/EEC, the Medical Device Directive
and is in compliance with procedures to produce products for sale in Europe. Any
failure by the Company to comply with QSR requirements or to maintain its
compliance with ISO 9001 (EN 46001) standards may result in the Company being
required to take corrective actions, such as modification of its policies and
procedures. In addition, the Company may be required to cease all or part of its
operations for some period of time until it can demonstrate that appropriate
steps have been taken to comply with QSR or ISO 9001 (EN 46001) standards. There
can be no assurance that the Company will be found in compliance with QSR by
regulatory authorities, or that it will continue to comply with ISO 9001 (EN
46001) standards in future audits or that the Company will not experience
difficulties in the course of developing its manufacturing capability. Any
failure of the Company to comply with state or FDA QSR requirements or to
maintain compliance with ISO 9001 (EN 46001) standards, or to develop its
manufacturing capability in compliance with such standards, would have a
material adverse effect on the Company's business, financial condition and
results of operations.
20
<PAGE>
The Company purchases certain key components of its products, including the
hydrophilic coating for certain of its microcatheters, from sole, single or
limited source suppliers. For certain of these components there are relatively
few alternative sources of supply. Establishing additional or replacement
suppliers for any of the numerous components used in the Company's products, if
required, may not be accomplished quickly and could involve significant
additional costs. Any supply interruption from vendors or failure of the Company
to obtain alternative vendors for any of the numerous components used to
manufacture the Company's products would limit the Company's ability to
manufacture its products and would have a material adverse effect on the
Company's business, financial condition and results of operations.
LIMITED SALES, MARKETING AND DISTRIBUTION EXPERIENCE
The Company has only limited experience marketing and selling its products
in commercial quantities. Expanding the Company's marketing and sales capability
to adequately support sales in commercial quantities will require substantial
effort and require significant management and financial resources. There can be
no assurance that the Company will be able to continue to build a marketing
staff or sales force, that expanding such a marketing staff or sales force will
be cost-effective or that the Company's sales and marketing efforts will be
successful. The Company's Cardima Pathfinder, Cardima Pathfinder AF and Tracer
microcatheter systems for mapping of AF and VT have obtained regulatory approval
in certain international markets, and sales and marketing of these products is
conducted primarily through distributors. The Company currently has a number of
exclusive distributors that cover certain European countries and Japan and has
sold only a limited number of Cardima Pathfinder, Cardima Pathfinder AF and
Tracer microcatheter systems through these distributors. The Company does not
have written agreements with certain of its exclusive distributors.
Consequently, the terms of such arrangements, such as length of arrangements and
minimum purchase obligations are uncertain. In addition, the laws in certain
international jurisdictions may make it difficult for the Company to terminate
such distribution arrangements absent specific written termination terms. There
can be no assurance that these distributors will be able to market and sell the
Company's products in these markets. There can be no assurance that the Company
will be able to enter into additional agreements with desired distributors on a
timely basis or at all, or that such distributors will devote adequate resources
to selling the Company's products. Failure to establish an adequate sales force
or to establish and maintain appropriate distribution relationships would have a
material adverse effect upon the Company's business, financial condition and
results of operations.
DEPENDENCE UPON KEY PERSONNEL
The Company's ability to operate successfully depends in significant part
upon the continued service of certain key scientific, technical, clinical,
regulatory and managerial personnel, and its continuing ability to attract and
retain additional highly qualified personnel in these areas. Competition for
such personnel is intense, especially in the San Francisco Bay Area, and there
can be no assurance that the Company can retain such personnel or that it can
attract or retain other highly qualified scientific, technical, clinical,
regulatory and managerial personnel in the future, including key sales and
marketing personnel.
21
<PAGE>
RISK OF PRODUCT LIABILITY; ADEQUACY OF INSURANCE COVERAGE
The development, manufacture and sale of the Company's microcatheter
systems may expose the Company to product liability claims. Although the Company
has not experienced any claims to date, there can be no assurance that the
Company will not experience losses due to product liability claims in the
future. Although the Company currently has general liability insurance with
coverage in the amount of $1.0 million per occurrence, subject to a $2.0 million
annual limitation, and product liability insurance with coverage in the amount
of $5.0 million per occurrence, subject to a $5.0 million annual limitation,
there can be no assurance that such coverage will continue to be available to
the Company on reasonable terms, if at all. In addition, there can be no
assurance that all of the activities encompassed within the Company's business
are or will be covered under the Company's policies. Although the Cardima
Pathfinder and Tracer products are labeled for single use only, the Company is
aware that some physicians are reusing such products. Moreover despite labeling
of the Company's microcatheters for diagnostic use only, the Company believes
that physicians are using such mapping microcatheters for ablation. Multiple use
or "off-label" use of the Company's microcatheters could subject the Company to
increased exposure to product liability claims, which could have a material
adverse effect on the Company's business, financial condition and results of
operations. The Company may require additional product liability coverage if the
Company significantly expands commercialization of its products. Such additional
coverage is expensive, difficult to obtain and may not be available in the
future on acceptable terms, if at all. Any claims or series of claims against
the Company, regardless of their merit or eventual outcome, could have a
material adverse effect on the Company's business, financial condition and
results of operations.
22
<PAGE>
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Not applicable.
Item 2. Changes in Securities
On June 5, 1997, the Company's Registration Statement on Form S-1 with
respect to the Company's initial public offering of 2,275,000 shares of the
Company's common stock was declared effective by the Securities and Exchange
Commission. These shares carry the same voting rights as previously issued
shares of common stock of the Company. Effective upon the closing of the
Company's initial public offering, all outstanding shares of preferred stock
were automatically converted into shares of the Company's common stock, and on
such date, the Company amended its Certificate of Incorporation to delete
reference to such preferred stock.
Item 3. Defaults Upon Senior Securities
Not applicable
Item 4. Submission of Matters to a Vote of Security Holders
On May 21, 1997 and June 4, 1997, the Company solicited stockholder approval to
approve the following matters:
<TABLE>
<CAPTION>
SHARES SHARES SHARES
FOR AGAINST NOT VOTED
--- ------- ---------
<S> <C> <C> <C>
Stockholder Action by Written Consent
on May 21, 1997:
Amendment to 1997 Stock Plan to
increase shares reserved under 1997
Stock Plan to 1,300,000 shares 4,644,339 0 927,132
Approval of 1997 Employee Stock
Purchase Plan with 250,000 shares
reserved for issuance 4,644,339 0 927,132
Approval of 1997 Directors' Stock
Option Plan with 200,000 shares
reserved for issuance 4,644,339 0 927,132
Approval of certain changes to the
Company's Bylaws 4,644,339 0 927,132
</TABLE>
23
<PAGE>
<TABLE>
<S> <C> <C> <C>
Approval of Company's Amended and
Restated Certificate of Incorporation
to be effective upon IPO
4,644,339 0 927,132
Stockholder Action by Written Consent
on June 4, 1997:
Amendment to Certificate of
Incorporation to permit automatic
conversion of the Company's Preferred
Stock at the IPO price 4,994,758 0 584,231
</TABLE>
Item 5. Other information
See Notes to Financial Statements.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits - See Index to Exhibits.
(b) No reports on Form 8-K were filed by the Registrant during the
quarter ended June 30, 1997.
24
<PAGE>
CARDIMA, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DATE: August 12, 1997 CARDIMA, INC.
/s/ Phillip C. Radlick, Ph.D.
--------------------------------
PHILLIP C. RADLICK, Ph.D.
President, Chief Executive Officer and Director
/s/ Ronald E. Bourquin
--------------------------------
RONALD E. BOURQUIN
Vice President and Chief Financial Officer
25
<PAGE>
CARDIMA, INC.
INDEX TO EXHIBITS FOR FORM 10-Q FOR QUARTER ENDED JUNE 30, 1997
EXHIBIT NO. EXHIBIT DESCRIPTION
- ----------- -------------------
11.1 Statement Regarding Computation of Net Loss Per Share
27.1 Financial Data Schedule
26
<PAGE>
EXHIBIT 11.1
CARDIMA, INC.
COMPUTATION OF NET LOSS PER SHARE
(in thousands, except per share data)
(unaudited)
<TABLE>
<CAPTION>
Three months ended Six months ended
June 30, June 30,
------------------ ------------------
1997 1996 1997 1996
-------- ------- ------- -------
<S> <C> <C> <C> <C>
Historical:
Weighted average common shares outstanding 2,277 72 1,175 71
Shares related to Staff Accounting Bulletins Nos. 55,
64 and 83:
Stock options - 632 316 632
Preferred Stock - 2,357 1,179 2,357
------- ------- ------- -------
Total shares used in calculating net loss per share 2,277 3,061 2,670 3,060
======= ======= ======= =======
Net Loss $(2,761) $(1,627) $(5,087) $(3,147)
======= ======= ======= =======
Net loss per share $ (1.21) $ (0.53) $ (1.91) $ (1.03)
======= ======= ======= =======
Pro forma:
Shares used in calculating net loss per share (per above) 2,277 3,061 2,670 3,060
Preferred Stock if converted 2,444 3,370 2,908 3,253
------- ------- ------- -------
Total shares used in calculating pro forma net loss per share 4,721 6,431 5,578 6,313
======= ======= ======= =======
Net Loss $(2,761) $(1,627) $(5,087) $(3,147)
======= ======= ======= =======
Pro forma net loss per share $ (0.58) $ (0.25) $ (0.91) $ (0.50)
======= ======= ======= =======
</TABLE>
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM SIX MONTHS
ENDED JUNE 30, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> JUN-30-1997
<CASH> 20,479
<SECURITIES> 0
<RECEIVABLES> 246
<ALLOWANCES> (85)
<INVENTORY> 586
<CURRENT-ASSETS> 21,525
<PP&E> 3,162
<DEPRECIATION> (975)
<TOTAL-ASSETS> 24,190
<CURRENT-LIABILITIES> 1,741
<BONDS> 0
0
0
<COMMON> 8
<OTHER-SE> 21,586
<TOTAL-LIABILITY-AND-EQUITY> 24,190
<SALES> 536
<TOTAL-REVENUES> 536
<CGS> 831
<TOTAL-COSTS> 831
<OTHER-EXPENSES> 4,846
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 81
<INCOME-PRETAX> (5,087)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (5,087)
<EPS-PRIMARY> 0
<EPS-DILUTED> 0
</TABLE>
